Enrolling study personnel in Ebola vaccine trials: from guidelines to practice in a non-epidemic context

Trials. 2019 Jul 11;20(1):422. doi: 10.1186/s13063-019-3487-0.

Abstract

Background: Enrolling participants in clinical trials can be challenging, especially with respect to prophylactic vaccine trials. The vaccination of study personnel in Ebola vaccine trials during the 2014-2016 epidemic played a crucial role in inspiring trust and facilitating volunteer enrollment. We evaluated the ethical and methodological considerations as they applied to an ongoing phase 2 randomized prophylactic Ebola vaccine trial that enrolled healthy volunteers in Guinea, Liberia, Sierra Leone, and Mali in a non-epidemic context.

Methods: On the assumption that the personnel on site involved in executing the protocol, as well as community mobilizers (not involved in the on-site procedures), might also volunteer to enter the trial, we considered both ethical and methodological considerations to set clear rules that can be shared a priori with these persons. We reviewed the scientific and gray literature to identify relevant references and then conducted an analysis of the ethical and methodological considerations.

Results: There are currently no regulations preventing a clinical investigator or site staff from participating in a trial. However, the enrollment of personnel raises the risk of undue influence and challenges the basic ethical principle of voluntary participation. The confidentiality of personal medical information, such as HIV test results, may also be difficult to ensure among personnel. There is a risk of disruption of trial operations due to the potential absence of the personnel for their commitment as trial participants, and there is also a potential for introducing differential behavior of on-site staff as they obtain access to accumulating information during the trial (e.g., the incidence of adverse events). Blinding could be jeopardized, given knowledge of product-specific adverse event profiles and the proximity to unblinded site staff. These aspects were considered more relevant for on-site staff than for community mobilizers, who have limited contact with site staff.

Conclusion: In a non-epidemic context, ethical and methodological considerations limit the collective benefit of enrolling site staff in a vaccine trial. These considerations do not apply to community mobilizers, whose potential enrollment should be considered as long as they meet the inclusion criteria and they are not exposed to any form of coercion.

Keywords: Clinical trials; Ebola vaccine; Employees; Ethics; Health workers; Low- and middle-income countries; Research participants; Site staff; Trial participants.

Publication types

  • Letter
  • Review

MeSH terms

  • Africa, Western
  • Attitude of Health Personnel
  • Clinical Trials, Phase II as Topic / ethics
  • Clinical Trials, Phase II as Topic / standards*
  • Ebola Vaccines / adverse effects
  • Ebola Vaccines / therapeutic use*
  • Eligibility Determination
  • Health Knowledge, Attitudes, Practice
  • Hemorrhagic Fever, Ebola / immunology
  • Hemorrhagic Fever, Ebola / prevention & control*
  • Hemorrhagic Fever, Ebola / virology
  • Humans
  • Multicenter Studies as Topic / ethics
  • Multicenter Studies as Topic / standards*
  • Patient Selection* / ethics
  • Practice Guidelines as Topic / standards*
  • Research Personnel / ethics
  • Research Personnel / psychology
  • Research Personnel / standards*
  • Research Subjects* / psychology

Substances

  • Ebola Vaccines